Jupiter Neurosciences, Inc.
JUNSJupiter Neurosciences is a clinical-stage pharmaceutical company focused on developing treatments for neuroinflammation and central nervous system (CNS) disorders.
Table of contents
Earnings
Next report
Sep 2, 2026 (in a month)Competitors
By market cap
By revenue growth
Profile
Jupiter Neurosciences is a clinical-stage pharmaceutical company focused on developing treatments for neuroinflammation and central nervous system (CNS) disorders. The company utilizes its proprietary JOTROL platform, an enhanced oral formulation of resveratrol designed to overcome historical bioavailability and gastrointestinal issues. Beyond its clinical pipeline, the company operates a consumer wellness division that markets science-backed nutritional supplements for longevity and performance.
A clinical-stage innovator leveraging a proprietary micellar technology to solve the bioavailability limitations of resveratrol for both medical and consumer applications.
Questions, answered.
- What is Jupiter Neurosciences, Inc.'s market cap?
- Jupiter Neurosciences, Inc. (JUNS) has a market capitalization of $5.5M and trades on XNAS.
- Who are Jupiter Neurosciences, Inc.'s competitors?
- Jupiter Neurosciences, Inc.'s key competitors include Biogen, Eli Lilly, Anavex Life Sciences, and others. These companies compete in similar markets and product categories.
- Who does Jupiter Neurosciences, Inc. partner with?
- Jupiter Neurosciences, Inc.'s notable partners include Aquanova, Catalent, Dominant Treasure Health Company Limited, and others.
- Where is Jupiter Neurosciences, Inc. headquartered?
- Jupiter Neurosciences, Inc. is headquartered in United States of America and employs approximately 5 people. It has been publicly traded since 2024.